Nanobiotix SA (NANOB.PA)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|2011||Chairman of the Supervisory Board|
|2013||Chairman of the Management Board and Chief Executive Officer|
|2013||Member of the Management Board, Chief Financial Officer,|
|2017||Chief Operating Officer|
|2008||Member of the Management Board, Medical Director, Development and Medical Affairs Department Director|
- BRIEF-Nanobiotix Did Not Generate Any Revenue In Q1
- BRIEF-Nanobiotix Partners With Weill Cornell Medicine
- BRIEF-Nanobiotix FY Net Loss Widens to 26.1 Million Euros
- BRIEF-Nanobiotix Presents Data From Phase I/II Liver Cancers Trial Of NBTXR3
- BRIEF-Nanobiotix Partners With The Providence Cancer Institute To Run Immunotherapeutic Preclinical Research In Pancreatic Cancers